Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Strains used in whole organism Plasmodium falciparum vaccine trials differ in genome structure, sequence, and immunogenic potential

8 Jan 2020

Abstract excerpt

Abstract Background Plasmodium falciparum (Pf) whole-organism sporozoite vaccines have been shown to provide significant protection against controlled human malaria infection (CHMI) in clinical trials. Initial CHMI studies showed significantly higher durable protection against homologous than heterologous strains, suggesting the presence of strain-specific vaccine-induced protection. However, interpretation of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genetics, Bioinformatics, and Biomedical Research
Share to Malaria Research and Control
Share to vaccines and immunoinformatics approaches

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31915075
DOI: 10.1186/s13073-019-0708-9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Strains used in whole organism Plasmodium falciparum vaccine trials differ in genome structure, sequence, and immunogenic potentialPMID 31915075Read ↗

Strains used in whole organism <i>Plasmodium falciparum</i> vaccine trials differ in genome structure, sequence, and immunogenic potentialSemantic proximity Read ↗

NF135.C10: a new Plasmodium falciparum clone for controlled human malaria infections.Semantic proximity Read ↗

Genome, proteome, and immunome data explain why 6 month controlled human malaria infection with sporozoites of the Pf7G8 clone of <i>Plasmodium falciparum</i> is a rigorous predictor of the efficacy of the PfNF54-based PfSPZ Vaccine in AfricaSemantic proximity Read ↗

Genome-based vaccine design: the promise for malaria and other infectious diseasesSemantic proximity Read ↗

RTS,S/AS01 malaria vaccine mismatch observed among Plasmodium falciparum isolates from southern and central Africa and globally.Semantic proximity Read ↗

Genetic diversity in the Plasmodium falciparum next-generation blood stage vaccine candidate antigen PfCyRPA in Senegal.Semantic proximity Read ↗

Genetic diversity in the Plasmodium falciparum next-generation blood stage vaccine candidate antigen PfCyRPA in SenegalSemantic proximity Read ↗

Genetic Diversity of Plasmodium falciparum (Pf) Field Isolates for the Development of Novel Controlled Human Malaria Infection (CHMI) Challenge StrainsSemantic proximity Read ↗

The genomes of three stocks comprising the most widely utilized live sporozoite Theileria parva vaccine exhibit very different degrees and patterns of sequence divergence.Semantic proximity Read ↗

Safety, infectivity and immunogenicity of a genetically attenuated blood-stage malaria vaccineSemantic proximity Read ↗

Genome Sequence, Transcriptome, and Annotation of Rodent Malaria Parasite Plasmodium Yoelii Nigeriensis N67Semantic proximity Read ↗

High quality chromosomal genome assemblies of three human Plasmodium species directly from natural infectionsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.